

BIOTRANSPLANT INC
Form 424B3
April 20, 2001

Filed Pursuant to Rule 424(b)(3)
Registration No. 333-94869

PROSPECTUS SUPPLEMENT
(To Prospectus Dated February 10, 2000)

BIOTRANSPLANT INCORPORATED
1,913,095 SHARES OF COMMON STOCK

The information in this prospectus supplement concerning the selling stockholders supplements the statements set forth under the caption "Selling Stockholders" in the prospectus. Capitalized items used and not defined herein shall have the meanings given to them in the prospectus. The information set forth under the caption "Selling Stockholders" in the prospectus is supplemented as follows:

SELLING STOCKHOLDERS

We issued 1,706,287 of the shares of common stock covered by this prospectus in a private placement on December 27, 1999. The remaining 206,808 shares of common stock, including the 60,610 shares of common stock underlying the warrants set forth below, were issued in private placements at various dates prior to our initial public offering in May 1996. Except as set forth below, none of the selling stockholders has held a position or office with, or has otherwise had a material relationship with us, within the past three years. The following table sets forth, to our knowledge, certain information about the selling stockholders as of December 31, 1999. Beneficial ownership is calculated based on SEC requirements and is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, each stockholder named in the table has sole voting and investment power with respect to all shares beneficially owned, subject to applicable community property laws. The percentage calculated for each selling stockholder is based upon the sum of the "Common Stock" and "Common Stock Issuable Upon Exercise of Warrants" columns.

We do not know when or in what amounts the selling stockholders may offer shares for sale. The selling stockholders may not sell all or any of the shares offered by this prospectus. Because the selling stockholder may offer all or some of the shares pursuant to this offering, and because there are currently no agreements, arrangements or understandings with respect to the sale of any of the shares that will be held by the selling stockholders after completion of the offering, we cannot estimate the number of the shares that will be held by the selling stockholders after completion of the offering. However, for purposes of this table, we have assumed that, after completion of the offering, none of the shares covered by this prospectus will be held by the selling stockholders.

Edgar Filing: BIOTRANSPLANT INC - Form 424B3

Name of Selling Stockholders	Number of Shares of Common Stock Beneficially Owned Prior to Offering		Percent	Number of Shares of Common Stock to be Sold	Number of Shares Beneficially Owned
	Number	Common Stock			
	Common Stock	Issuable Upon Exercise of Warrants			

Larry Abrams	22,500	553	*	13,053	10,000
Aries Domestic Fund II, L.P.	12,909	0	*	12,909	0

Name of Selling Stockholders	Number of Shares of Common Stock Beneficially Owned Prior to Offering		Percent	Number of Shares of Common Stock to be Sold	Number of Shares Beneficially Owned
	Number	Common Stock			
	Common Stock	Issuable Upon Exercise of Warrants			

Aries Domestic Fund, L.P.	165,593	0	1.6%	165,593	0
Aries Master Fund	411,498	0	4.0%	411,498	0
BioLease, Inc.(1)	77,448	0	*	77,448	0
Core Technology Fund Inc.	34,600	0	*	34,600	0
EGM Medical Technology Offshore Fund	89,000	0	*	89,000	0
Executive Technology L.P.	13,500	0	*	13,500	0
Peter Feinstein	6,250	0	*	6,250	0
Henry L. Foster(2)	50,000	0	*	50,000	0

Edgar Filing: BIOTRANSPLANT INC - Form 424B3

H&Q HealthCare Investors	429,898	10,210	4.3%	10,210	429,898
H&Q Life Sciences Investors	282,620	17,722	2.7%	17,722	282,620
Little Wing, L.P.	232,965	0	2.3%	232,965	0
Little Wing, L.P. TOO	82,120	0	*	82,120	0
Matrix Technology Group, N.V.	7,400	0	*	7,400	0
Merlin BioMed International, Ltd.	50,000	0	*	50,000	0
Merlin BioMed, L.P.	40,000	0	*	5,555	0
ML-Lee Acquisition Fund(1)	0	10,014	*	10,014	0
ML-Lee Acquisition Fund (Retirement Account) II, L.P.(1)	0	6,554	*	6,554	0
Narragansett I, L.P.	114,110	0	1.1%	114,110	0
Narragansett Offshore, Ltd.	30,334	0	*	30,334	0
Perceptive Life Sciences, L.P.	44,444	0	*	44,444	0

- 2 -

Name of	Number of Shares of Common Stock Beneficially Owned Prior to Offering		Number of Shares of Common Stock to be Sold	Number of Share Beneficially O
	Number	Percent		
	Common Stock Issuable			
				Com I

Edgar Filing: BIOTRANSPLANT INC - Form 424B3

Selling Stockholders	Common Stock	Upon Exercise of Warrants		Common Stock	Upon of
-----	-----	-----		-----	-----
Neil St. John Raymond(1)	0	15,557	*	15,557	0
Wayne P. Rothbaum	45,000	0	*	45,000	0
Sci-Tech Investment Partners	23,700	0	*	23,700	0
SG Partners L.P.	52,700	0	*	52,700	0
Mitchell D. Silber	33,400	0	*	33,400	0
Tradewind Fund, Ltd.	129,359	0	1.3%	129,359	0
Ursus Capital, L.P.	35,000	0	*	35,000	0
Yale University	83,500	0	*	83,500	0
Yale University Retirement Plan for Staff Employees	9,600	0	*	9,600	0

*Represents beneficial ownership of less than one percent of our common stock.

(1) We make payments to BioLease, Inc. pursuant to the terms of a lease agreement with BioLease for our facilities in Charlestown, Massachusetts. Neil St. John Raymond, ML-Lee Acquisition Fund and ML-Lee Acquisition Fund (Retirement Accounts) II, L.P. are affiliates of BioLease.

(2) Henry L. Foster is the father of James C. Foster, a director of the Company.

The date of this Prospectus Supplement is April 20, 2001